Literature DB >> 17885537

Hypertension and target organ damage in children and adolescents.

Empar Lurbe.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17885537     DOI： 10.1097/HJH.0b013e3282f051b4

Source DB:  PubMed          Journal:  J Hypertens        ISSN： 0263-6352            Impact factor:   4.844


× No keyword cloud information.
  5 in total

1.  The relationship between currently recommended ambulatory systolic blood pressure measures and left ventricular mass index in pediatric hypertension.

Authors:  Bojko Bjelakovic; Vincent W V Jaddoe; Vladislav Vukomanovic; Stevo Lukic; Sergej Prijic; Milos Krstic; Ljiljana Bjelakovic; Ljiljana Saranac; Ana Velickovic
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

2.  Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension.

Authors:  Thomas Wells; Jeffrey Blumer; Kevin E C Meyers; Jose P R Neto; Rejane Meneses; Mieczysław Litwin; Johan Vande Walle; Susan Solar-Yohay; Victor Shi; Guangyang Han
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-03-18       Impact factor: 3.738

3.  Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension.

Authors:  Randall Lou-Meda; Brigitte Stiller; Zenaida L Antonio; Ewa Zielinska; Hui-Kim Yap; Hee Gyung Kang; Monique Tan; Robert D Glazer; Michele A Valentin; Linda Wang
Journal:  Pediatr Nephrol       Date:  2018-11-05       Impact factor: 3.714

Review 4.  Clinical assessment of hypertension in children.

Authors:  Nisarg Patel; Nicole Walker
Journal:  Clin Hypertens       Date:  2016-05-17

5.  The incidence of collagen-associated adverse events in pediatric population with the use of fluoroquinolones: a nationwide cohort study in Taiwan.

Authors:  Pei-Han Yu; Chih-Fen Hu; Jen-Wei Liu; Chi-Hsiang Chung; Yong-Chen Chen; Chien-An Sun; Wu-Chien Chien
Journal:  BMC Pediatr       Date:  2020-02-11       Impact factor: 2.125
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.